Clofarabine

Drug Profile

Clofarabine

Alternative Names: CAFdA; Cl-F-ara-A; Clofaribine; Clolar; Evoltra; GZ393590; JC0707; SAR 393590

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Southern Research Institute
  • Developer Bioenvision; Dana-Farber Cancer Institute; Erasmus MC; Genzyme Corporation; Genzyme Oncology; Massachusetts General Hospital; Oncology Specialists S.C.; Sanofi Genzyme; Sanofi Oncology; University of Michigan Comprehensive Cancer Center; Yale University
  • Class Antineoplastics; Purine nucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Acute lymphoblastic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia
  • Phase II Histiocytosis
  • Phase I/II Haematological malignancies
  • Preregistration Submission Withdrawal Acute myeloid leukaemia
  • Discontinued B cell lymphoma; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Psoriasis; Solid tumours

Most Recent Events

  • 09 Jan 2017 Phase I/II development is ongoing in Haematological malignancies (Second-line therapy or greater, Combination therapy) in USA (NCT00824135)
  • 01 Dec 2016 Sanofi completes the phase I REFLEX trial for Haematological malignancies (Second line therapy or greater, Combination therapy) in USA (NCT00824135)
  • 01 Apr 2016 Genzyme completes a phase II trial in Acute lymphoblastic leukaemia (Combination therapy) in USA (IV) (NCT00973752)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top